← board
ANEB
Anebulo Pharmaceuticalsdistress 4/10 · elevated risk$0.300%today-91% from 52w high
Lead: Healthy Volunteers
Revenue
pre-revenue
Liquidity
$9M
Runway
1.4 yrs
Shares 1y
-1%
Price & events
-72.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+29900.0%
1W
-14.3%
1M
-31.2%
3M
-72.7%
6M
-83.6%
1Y
-87.5%
2Y
-96.0%
5Y
-95.8%
All
Overview
- Market Cap
- $12.24M
- Volume
- 1.20K
- 52 Week Range
- $0.00 – $3.33
- Total Shares
- 40.78M
- Float Shares
- 24.13M
- Short %
- 2.20%
- % Held by Insiders
- 40.84%
- % Held by Institutions
- 0.00%
- RVOL
- 1.07x
- Beta
- -1.84
Pipeline stages · 1 programs
selonabant
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-05-06 | Phase 1 | selonabant | Healthy Volunteers | 40 | completed |
Catalyst news & presentations · 2
- first half of 2025trial initiationsecondaryPhase 1selonabant · Phase 1 SAD study of intravenous selonabant in healthy adultsSEC 8-K
- 2024-07-22partnershipselonabant · Awarded up to $1.9M cooperative grant from NIDA/NIH to support development of intravenous selonabant for acute cannabis-induced toxicities.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-07-23Maxim GroupBuy → Hold
- 2025-05-15Maxim GroupBuy
- 2024-11-19BenchmarkSpeculative Buy
- 2024-10-01BenchmarkSpeculative Buy
Competitors — Healthy Volunteers
- SNYSanofi$52.5B · D1
- ALNYALNYLAM PHARMACEUTICALS, INC.$35.3B · D1
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- KYMRKymera Therapeutics, Inc.$9.1B · D5
- SRRKScholar Rock Holding Corp$5.7B · D2
- AGIOAGIOS PHARMACEUTICALS, INC.$2.1B · D5
- GLUEMonte Rosa Therapeutics, Inc.$2.0B · D4
- SVASINOVAC BIOTECH LTD$465M · D0
- CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
- APGEApogee Therapeutics, Inc.— · D2
Recent news
- 2026-07-18Anebulo Pharmaceuticals (ANEB) Proxy Filing Summary - Quartr
- 2026-06-25Anebulo Pharmaceuticals, Inc. Actuals & Estimates (OTC:ANEB) - TradingView
- 2026-06-18Anebulo Pharmaceuticals Inc - TradingKey
- 2026-02-06Anebulo Pharmaceuticals stock plunges after announcing Nasdaq delisting plans - Investing.com
- 2026-02-06Anebulo Pharmaceuticals Announces Intention To Voluntarily Delist From Nasdaq And Deregister With SEC - TradingView
- 2026-02-06Anebulo Pharmaceuticals Announces Voluntary Nasdaq Delisting Plan - TipRanks
- 2026-02-06Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC - Business Wire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.